The influence of corticosteroids on IL-6/IL-6R system in patients with Graves' ophthalmopathy;Wpływ kortykosteroidów na układ IL-6/IL-6R u chorych z oftalmopatia̧ w przebiegu choroby Gravesa-Basedowa

Polskie Archiwum Medycyny Wewnetrznej

Volumn 108, Issue 2, 2002, Pages 739-744

  Myśliwiec, Janusz ^a   Krȩtowski, Adam ^a   Topolska, Jolanta ^a   Stȩpień, Agnieszka ^a   Kinalska, Ida ^a  

^a Klinika Endokrynologii   (Poland)

Author keywords

Graves' ophthalmopathy; IL 6; IL 6R

Indexed keywords

CORTICOSTEROID; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHYLPREDNISOLONE; PREDNISONE;

ADULT; AGED; ANAMNESIS; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOPHTHALMOS; EYE DISEASE; FEMALE; GRAVES DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MALE; PATHOGENESIS; PROGNOSIS; RANK SUM TEST; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

EID: 0036042229     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bartley G., Fatourechi V., Kadmas E. i wsp.: Clinical features, of Graves' ophthalmopathy in an incidence cohort. Am. J. Ophthalmol., 1996, 121, 284.
2. Mourits M., Koorneef L., Wiersinga W.M., Prummel M.F., Berghout A., Gaag R.D.: Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Brit. J. Ophtalmol., 1989, 73, 639.
3. Just M., Kahaly G., Higer H.: Graves' ophtalmopathy: role of MR imaging in radiotherapy. Radiology, 1991, 179, 197.
4. Postema P.T.E., Krenning E.P., Wijngaarde R.: [111 In-DPTA-D-Phe 1] Octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? J. Clin. Endocrinol. Metab., 1994, 79, 1845.
5. Kahaly G., Schulter M., Sewell A.C., Bernhard G., Beyer J., Krause U.: Urinary glycosaminoglycans in Graves' ophtalmopathy. Clin. Endocrinol., 1990, 33, 35.
6. Natt N., Bahn R.S.: Cytokines in the evolution of Graves' ophthalmopathy. Autoimmunity, 1997, 26, 129.
7. Hiromatsu Y., Yang D., Bednarczuk T., Miyake I., Nonaka K., Inoue Y.: Cytokine profiles in eye muscle tissue and orbital fat from patients with thyroid associated ophthalmopathy. J. Clin. Endocrinol. Metab., 2000, 85, 1194.
8. Weyend C.M., Fulbright J.W., Evans J.M., Hunder G.G., Goronzy J.J.: Corticosteroid requirements in polymyalgia rheumatica. Arch. Intern. Med., 1999, 59, 577.
9. Bartalena L., Brogioni S., Grosso L., Bogazzi F., Burelli A., Maruno E.: Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J. Clin. Endocrinol. Metab., 1996, 81, 2930.
10. Spadaro A., Taccari E., Riccieri V., Sensi F., Sili Scavalli A., Zoppini A.: Interleukin-6 and soluble interleukin-2-receptor in psoriatic arthritis: correlations with clinical and laboratory parameters. Clin. Exp. Rheumatol., 1996, 14, 413.
11. Mourits M., Koorneef L., Wiersinga W.M., Prummel M.F. Berghout A., Gaag R.D.: Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Bri. J. Ophthalmol., 1989, 73, 639.
12. Tallstedt L., Lundell G., Torring O.: Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N. Engl. J. Med., 1992, 326, 1733.
13. Prummel M.F., Wiersinga W.: Smoking and risk of Graves' disease. JAMA, 1993, 269, 479.
14. Bartalena L., Marcocci C., Tanda M. i wsp.: Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Ann. Intern. Med., 1998, 129, 632.
15. Jones T.H.: Interleukin-6 an endocrine cytokine. Clin. Endocrinol. (Oxf), 1994, 40, 703.
16. Weetman A.P., Bright-Thomas R., Freeman M.: Regulation of interleukin-6 release by human thyrocytes. J. Endocrinol, 1990, 127, 357.
17. Heufelder A.E., Bahn R.S.: Modulation of Graves, orbital fibroblast proliferation by cytokines and glucocorticoid receptor agonists. Invest. Ophtalmol. Vis. Sci.), 1994, 35, 120.
18. Montero-Julian F.A.: The soluble IL-6 receptor: serum levels and biological function. Cell. Mol. Biol., 2001, 47, 583.
19. Wakelkamp L.M., Gerding M.N., Van der Meer J.W., Prummel M.F., Wiersinga W.M.: Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy. Clin. Exp. Immunol., 2000, 121, 453.
20. Salvi M., Pedrazzoni M., Girasole G. i wsp.: Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur. J. Endocrinol., 2000, 143, 197.
21. Molnar L., Balazs C.: High circulating IL-6 level in Graves' ophthalmopathy. Autoimmunity, 1997, 25, 91.
22. Myśliwiec J., Krȩtowski A., Topolska J. i wsp.: The influence of corticosteroids on systemie cytokines of humoral and cell-mediated immune response in Graves' ophthalmopathy. Hormon Metabolic Research (w druku).
23. Jones S.A, Horiouchi S., Topley N., Yamamoto N., Fuller G.M.: The soluble interleukin receptor: mechanisms of production and implications in disease. FASEB J., 2001, 15, 43.